Royalty Report: Drugs, cardiac – Collection: 248346

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • cardiac

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 248346

License Grant
The Licensor of India hereby grants to Licensee an exclusive option to acquire an exclusive, royalty bearing license and sublicense rights to the Licensor Intellectual Property in the Field in the Territory, (the Option).  Licensee may exercise the Option during the Option Period by delivering written notice to Licensor of Licensee’s exercise of the Option on or before the expiration of the Option Period.

Effective as of the Option Exercise Date, subject to and upon the terms and conditions set forth herein, Licensor hereby grants Licensee an exclusive, royalty bearing license (with the right to sublicense as provided) to Licensor Intellectual Property to Develop, make, have made, use, offer for sale, sell and import the Compound and the Licensed Products in the Territory and the Field.

License Property
Licensed Product means any product (i) which contains the Compound, or any isomer, homolog, analog or prodrug of the Compound, or (ii) which, if made, used or sold in the absence of the license granted by Licensor to Licensee under this Agreement, would infringe an Enforceable Claim of a Licensor Patent or Joint Patent.

Compound means (a) r<3R.5R}-7-[2-(4-fluorophenvl}-4-({[4-(hydroxymethyl} phenyl) amino} carbonyl}-5-isopropyl-3-phenyl-lH-pyrrol-1-yll-3.5-dihydroxy-heptanoic acid]; (b) any pharmaceutically acceptable salt of the foregoing; (c) any active metabolite of the foregoing; (d) any isomer of the foregoing; (e) any enantiomer of the foregoing; and (f) any prodrug of the foregoing.

Licensor Patents means
United States of America Application Serial No. 10/558.859
United States of America Application Serial No. 101449.418

Field of Use
Field means all human uses.
The Licensee intends to develop the statin as a treatment for dyslipidemia.  Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle.

IPSCIO Record ID: 294283

License Grant
Licensor grants to the Licensee of Japan an exclusive license in the Territory to use Licensor Know-how and the Licensed Compound to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell Licensed Product(s).

Licensor grants to an exclusive license in the Territory under the Patent Rights to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell the Licensed Compound, solely for use as an active ingredient in Licensed Products and Licensed Products.

License Property
Licensor has Know-How and the Patent Rights relating to the antidyslipidemic compound known as BT16.

BT/6 shall mean any form, including, without limitation, any salt, hydrate, crystalline structure or the like, of the small molecule compound identified by the chemical name B,B-tetramethyl hexadecane-a, (.)-dioic acid.

BT 2000 shall mean the compounds covered by PCT Patent W098/30530 including, without limitation, B, B -tetramethyloctadecanedioic acid.

Licensed Compound shall mean BT16.

The patents include Use of alpha, omega-dicarboxylic acids as fibrinogen sinkers, and, Pharmaceutical compositions containing carboxylic acids and derivatives thereof, and, Methods of administering 3,3,14,14 terramethyl hexadecane 1,16 dioic acid.

BT16 was found to have a potent efficacy of suppressing triglyceride levels in animal and human studies. Further studies demonstrated that it has also insulin-sensitizing properties and the possibility of this compound being developed as a metabolic syndrome therapy in the future has been suggested.

Field of Use
The phase II compound BT16 is r the treatment of dyslipidemia.

Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle.  Dyslipidemia increases the chance of clogged arteries (atherosclerosis) and heart attacks, stroke, or other circulatory concerns, especially in smokers.

Licensee possesses extensive capabilities in the development and commercialization of pharmaceutical products in Japan and in certain countries in Asia.  Licensor is a clinical-stage pharmaceutical company engaged in discovering and developing novel RNAi interference or RNAi-based therapeutics.

IPSCIO Record ID: 347182

License Grant
Licensor will grant Licensee exclusive development and commercialization rights to bempedoic acid and the bempedoic acid /ezetimibe combination tablet for purposes of treating hyperlipidemia in humans (the Field) in the following territories South Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar (the Daiichi Territory).
License Property
Bempedoic acid and the bempedoic acid /ezetimibe combination tablet is a oral, small molecule in fixed-dose combination developed to lower elevated LDL-C (low-density lipoprotein cholesterol) to help patients who still need additional lipid lowering despite taking maximally tolerated statin therapy.
Field of Use
Field of use is for purposes of treating hyperlipidemia in humans.

Hyperlipidemia is an abnormally high concentration of fats or lipids in the blood commonly known as high cholesterol.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.